Literature DB >> 25943495

AAV's Golden Jubilee.

Nicholas Muzyczka1, Kenneth I Berns2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25943495      PMCID： PMC4427886          DOI： 10.1038/mt.2015.55

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  26 in total

1.  ADENOVIRUS-ASSOCIATED DEFECTIVE VIRUS PARTICLES.

Authors:  R W ATCHISON; B C CASTO; W M HAMMON
Journal:  Science       Date:  1965-08-13       Impact factor: 47.728

2.  Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap.

Authors:  J E Conway; S Zolotukhin; N Muzyczka; G S Hayward; B J Byrne
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo.

Authors:  H Nakai; S R Yant; T A Storm; S Fuess; L Meuse; M A Kay
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Novel tools for production and purification of recombinant adenoassociated virus vectors.

Authors:  D Grimm; A Kern; K Rittner; J A Kleinschmidt
Journal:  Hum Gene Ther       Date:  1998-12-10       Impact factor: 5.695

5.  Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

6.  A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease.

Authors:  T Flotte; B Carter; C Conrad; W Guggino; T Reynolds; B Rosenstein; G Taylor; S Walden; R Wetzel
Journal:  Hum Gene Ther       Date:  1996-06-10       Impact factor: 5.695

7.  In vivo model of adeno-associated virus vector persistence and rescue.

Authors:  S A Afione; C K Conrad; W G Kearns; S Chunduru; R Adams; T C Reynolds; W B Guggino; G R Cutting; B J Carter; T R Flotte
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

8.  Site-specific integration by adeno-associated virus.

Authors:  R M Kotin; M Siniscalco; R J Samulski; X D Zhu; L Hunter; C A Laughlin; S McLaughlin; N Muzyczka; M Rocchi; K I Berns
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

9.  Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease.

Authors:  Deniz Kirik; Lucy E Annett; Corinna Burger; Nicholas Muzyczka; Ronald J Mandel; Anders Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-24       Impact factor: 11.205

10.  Adeno-associated virus vectors can be efficiently produced without helper virus.

Authors:  T Matsushita; S Elliger; C Elliger; G Podsakoff; L Villarreal; G J Kurtzman; Y Iwaki; P Colosi
Journal:  Gene Ther       Date:  1998-07       Impact factor: 5.250
View more
  8 in total

Review 1.  Next Generation of Adeno-Associated Virus Vectors for Gene Therapy for Human Liver Diseases.

Authors:  Kenneth I Berns; Arun Srivastava
Journal:  Gastroenterol Clin North Am       Date:  2019-04-01       Impact factor: 3.806

Review 2.  Gene Therapy for Hemophilia.

Authors:  Arthur W Nienhuis; Amit C Nathwani; Andrew M Davidoff
Journal:  Mol Ther       Date:  2017-04-11       Impact factor: 11.454

Review 3.  Nanotherapy for Duchenne muscular dystrophy.

Authors:  Michael E Nance; Chady H Hakim; N Nora Yang; Dongsheng Duan
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-04-11

Review 4.  Systemic delivery of adeno-associated viral vectors.

Authors:  Dongsheng Duan
Journal:  Curr Opin Virol       Date:  2016-07-25       Impact factor: 7.090

Review 5.  Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies.

Authors:  Sebastian P Fuchs; Ronald C Desrosiers
Journal:  Mol Ther Methods Clin Dev       Date:  2016-11-16       Impact factor: 6.698

6.  Tyrosine triple mutated AAV2-BDNF gene therapy in an inner retinal injury model induced by intravitreal injection of N-methyl-D-aspartate (NMDA).

Authors:  Asaka Lee Shiozawa; Tsutomu Igarashi; Maika Kobayashi; Kenji Nakamoto; Shuhei Kameya; Shigeto Fujishita; Hiroshi Takahashi; Takashi Okada
Journal:  Mol Vis       Date:  2020-06-03       Impact factor: 2.367

Review 7.  Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy.

Authors:  Dongsheng Duan
Journal:  Mol Ther       Date:  2018-07-17       Impact factor: 11.454

8.  Rational engineering of a functional CpG-free ITR for AAV gene therapy.

Authors:  Xiufang Pan; Yongping Yue; Maria Boftsi; Lakmini P Wasala; Ngoc Tam Tran; Keqing Zhang; David J Pintel; Phillip W L Tai; Dongsheng Duan
Journal:  Gene Ther       Date:  2021-10-06       Impact factor: 4.184
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.